ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Fred Vogt, Iovance Biotherapeutics"
Episode Synopsis
This episode features Fred Vogt, Interim CEO at Iovance Biotherapeutics, recipient of the 2024 Patient Impact Award. In this episode, Fred shares the journey behind AMTAGVI - the first FDA approved tumor infiltrating lymphocyte (TIL) therapy. Learn about the clinical trial process, how they brought this groundbreaking treatment to market, the impact the Iovance team has on the life sciences industry and how the state of Pennsylvania is supporting Iovance's efforts to treating patients.
More episodes of the podcast Being a Life Sciences Leader
Bill Sibold, Madrigal Pharmaceuticals
29/04/2025
Devlin Robinson, PA State Senate
25/03/2025
Ben Doranz, PhD, MBA, Integral Molecular
11/03/2025
Adrian Rawcliffe, Adaptimmune
05/03/2025
Rob Albert, B. Braun
20/02/2025
Adele Oliva, 1315 Capital
29/01/2025
Jeff O'Donnell, Runway Healthcare
22/01/2025
In God we trust